ArticleNeuropsychiatric disease and treatment2025
Differentiations in Illness Duration, Thyroid-Stimulating Hormone, Glucose and P300 Latency Between Drug-Naïve Unipolar and Bipolar Depression: A Comparative Cross-Sectional Study.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cognitive impairment in comorbid MDD and OSA: the dual effects of intermittent hypoxia and sleep fragmentation.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Distinguishing bipolar depression (BD) from unipolar depression (UD) remains a major clinical challenge, especially in drug-naïve patients. The present study aimed to investigate whether demographic, clinical, and biochemical parameters can help differentiate drug-naïve BD from UD. Methods: Drug-naïve patients with UD and BD were recruited from Shandong Mental Health Center. Ninety-four inpatients (61 UD and 33 BD) were assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17) and P300 latency. Fasting serum levels of free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), as well as fasting plasma glucose (FPG), lipid, C-reactive protein (CRP), and uric acid (UA) indicators were measured. Results: Patients with BD had longer illness duration and P300 latency and lower FT3 levels, but higher levels of TSH and FPG than patients with UD (all Conclusion: Increased illness duration, serum TSH and FPG levels, and P300 latency were independent risk factors for BD. Demographic, clinical, biochemical, and electrophysiological markers identified may have the potential to distinguish BD from UD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.